1. Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results From the Randomized CANVAS Program Trials. Issue 2 (February 2019) Authors: Zhou, Zien; Lindley, Richard I.; Rådholm, Karin; Jenkins, Bronwyn; Watson, John; Perkovic, Vlado; Mahaffey, Kenneth W.; de Zeeuw, Dick; Fulcher, Greg; Shaw, Wayne; Oh, Richard; Desai, Mehul; Matthews, David R.; Neal, Bruce Journal: Stroke Issue: Volume 50:Issue 2(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cardiac Safety Research Consortium (CSRC): Cardiovascular Safety and Adverse Event Case Report Forms. (July 2015) Authors: Sabol, Mary Elizabeth; Finkle, John; Krucoff, Mitch; Stockbridge, Norman; Parkhill, Nancy; Shinagawa, Kaori; Mahaffey, Kenneth; Tcheng, James; Lenihan, Daniel; Melloni, Chiara; Todaro, Thomas; Michelson, Eric; Munley, Jiefen; Zander, Judith; Oh, Richard Journal: Therapeutic innovation & regulatory science Issue: Volume 49:Number 4(2015:Jul.) Page Start: 511 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. Issue 10 (24th June 2020) Authors: Arnott, Clare; Huang, Yuli; Neuen, Brendon L; Di Tanna, Gian Luca; Cannon, Christopher P.; Oh, Richard; Edwards, Robert; Kavalam, Mary; Rosenthal, Norman; Perkovic, Vlado; Jardine, Meg J; Mahaffey, Kenneth; Neal, Bruce Journal: Diabetes, obesity & metabolism Issue: Volume 22:Issue 10(2020) Page Start: 1753 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. (December 2019) Authors: Li, JingWei; Badve, Sunil V; Zhou, Zien; Rodgers, Anthony; Day, Richard; Oh, Richard; Lee, Mary; Perkovic, Vlado; de Zeeuw, Dick; Mahaffey, Kenneth W; Fulcher, Greg; Matthews, David R; Neal, Bruce Journal: Lancet Issue: Volume 1:Number 4(2019) Page Start: e220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer. (December 2021) Authors: Wang, Feihu; Su, Hao; Xu, Dongqing; Monroe, Maya K.; Anderson, Caleb F.; Zhang, Weijie; Oh, Richard; Wang, Zongyuan; Sun, Xuanrong; Wang, Han; Wan, Fengyi; Cui, Honggang Journal: Biomaterials Issue: Volume 279(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗